Abstract-We performed a pilot investigation of the cardiopulmonary baroreflex control of ventricular contractility in two conscious dogs. We specifically measured spontaneous beat-to-beat hemodynamic variability before and after the administration of propranolol. We then identified the transfer function relating beat-to-beat fluctuations in central venous pressure (CVP) to maximal ventricular elastance (E max ) to characterize the cardiopulmonary baroreflex control of ventricular contractility, while accounting for the influences of arterial blood pressure fluctuations on E max via the arterial baroreflex and heart rate fluctuations on E max via the force-frequency relation. Our major finding is that the cardiopulmonary baroreflex responds to an increase (decrease) in CVP by increasing (decreasing) E max via the β-sympathetic nervous system.
I. INTRODUCTION
HE baroreflex systems are primarily responsible for maintaining blood pressures over short time scales of seconds to minutes. It is well known that the arterial baroreflex senses arterial blood pressure (ABP) via baroreceptors lying in the carotid sinus and aortic arch and buffers a decrease (increase) in ABP by increasing (decreasing) heart rate (HR), total peripheral resistance, and ventricular contractility. However, the cardiopulmonary baroreflex is less understood. The sensory receptors of this system are more complex, residing mainly in the cardiac chambers but also in the walls of the pulmonary artery [1] . These receptors have been shown to be very responsive to central venous pressure (CVP) [2, 3] . The cardiopulmonary baroreflex responds to a change in CVP by inducing an opposite change in total peripheral resistance [3, 4] . An increase in CVP also leads to an increase in HR (i.e., Bainbridge effect) in dogs [5] , but an opposite change may occur in humans [2] .
To our knowledge, the cardiopulmonary baroreflex control of ventricular contractility has not been elucidated. A change in CVP could induce a same directional change in ventricular contractility so as to maintain CVP, much like the Bainbridge effect. On the other hand, a change in CVP could cause an opposite change in ventricular contractility in order to blunt the forthcoming change in ABP due to the altered preload, much like the cardiopulmonary baroreflex control of total peripheral resistance.
We performed a pilot canine investigation of the cardiopulmonary baroreflex control of ventricular contractility. More specifically, we measured spontaneous beat-to-beat hemodynamic variability from two conscious dogs during control conditions and from one of the dogs after the administration of propranolol to abolish the neural control of ventricular contractility. We then identified the transfer function relating beat-to-beat fluctuations in CVP to maximal ventricular elastance (E max ), which is perhaps the best available index of ventricular contractility [6] [7] [8] , while accounting for other influences on E max including ABP fluctuations via the arterial baroreflex.
II. METHODS

A. Data Collection
We collected pilot hemodynamic data for this study from two adult dogs (20-25 kg) in the context of performing experiments to address unrelated specific aims. We describe only those aspects of the experimental procedures that were relevant to the present study. All procedures were reviewed and approved by the Wayne State University Animal Investigator Committee.
We studied each dog on three experimental days with suitable recovery periods in between as follows. On the first day, we performed a midline sternotomy under sterile conditions. We installed instrumentation including two pairs of sonomicrometry crystals (Sonometrics) on the left ventricular (LV) endocardium for continuous LV volume (LVV) as described in [9] ; a fully implanted system with a micromanometer-tipped catheter (Data Sciences International) in the left ventricle (LV) for continuous LV pressure (LVP); an ultrasonic flow probe (Transonic Systems) around the ascending aorta for continuous cardiac output; and hydraulic vascular occluders (In Vivo Metrics) on the superior and inferior vena cava to diminish cardiac preload. Then, on the second day, we installed additional instrumentation under sterile conditions including fluid-filled catheters in the terminal aorta for continuous ABP and in the right atrium for continuous CVP. Finally, on the third day, we recorded the cardiovascular measurements during a baseline period of 5-8 min and transient vena cava occlusion while the dogs were standing quietly. For the second dog, we then administered propranolol to achieve complete β-sympathetic nervous blockade and likewise recorded the measurements.
B. Data Analysis
We analyzed the hemodynamic data for the three conditions of the two dogs. First, we determined E max and CVP, along with ABP and HR, on a beat-to-beat basis from the continuous measurements during the baseline period. Then, we identified the transfer function relating the spontaneous beat-to-beat fluctuations in CVP to E max (CVP→E max ), while effectively eliminating the known influences of beat-to-beat ABP and HR fluctuations on E max .
More specifically, as described in a companion study of dynamic E max control before and after heart failure [10] , we estimated beat-to-beat E max during the baseline period according to the procedure shown in Fig. 1 . First, we applied the traditional method for determining E max by performing linear regression on the end-systolic LVP-LVV points during the transient vena cava occlusion [11] . The slope of the resulting line represents the average E max , while the x-intercept indicates the LV unstressed volume (V 0 ). Then, assuming constant V 0 , we computed the time-varying LV elastance (LVE) curve from the continuous LVP and LVV during the baseline period by dividing the former measurement by the difference between the latter measurement and V 0 . Finally, we determined E max on a beat-to-beat basis by identifying the maximum of the LVE curve over each beat. We computed beat-to-beat CVP and ABP by respectively time averaging the continuous CVP and ABP over each beat during the baseline period and identified beat-to-beat HR from the continuous cardiac output during the same period. We then re-sampled the E max , CVP, ABP, and HR beat series to time series at a sampling frequency of 1 Hz as described in [12] .
We identified the CVP→E max transfer function by analyzing all four of the time series according to the block diagram illustrated in Fig. 2 . As indicated in this diagram, we simultaneously identified the transfer function relating beat-to-beat fluctuations in ABP to E max (ABP→E max ), which characterizes the arterial baroreflex, and the transfer function relating beat-to-beat fluctuations in HR to E max (HR→E max ), which characterizes the force-frequency relation. In this way, the influence of beat-to-beat fluctuations in CVP on E max was isolated from other major confounding factors. We also estimated the perturbing noise source ; and the unknown model order, p, q, r, s, m, and n, limit the number of parameters [13] . For a fixed model order, we analytically estimated the parameters from zero-mean fluctuations in the 1 Hz CVP, ABP, HR, and E max time series by linear least squares minimization of max E W [13] . We set p, r, and m to two, q, and s, respectively, on the basis of a compelling previous study demonstrating that the arterial baroreflex control of E max could be well represented as a second-order delay system [14] . We determined q, s, and n by minimization of the popular minimum description length criterion [13] . 
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⋅
III. RESULTS
Figs. 3 and 4 illustrate the CVP→E max , ABP→E max , and HR→E max transfer functions in terms of intuitive step responses, respectively, from the first dog during the control condition and the second dog during the control and propranolol conditions. During the control condition, both CVP→E max step responses indicate that E max would increase in response to a step increase in CVP. Quantitatively, the average gain value and dominant time constant of these steps responses are 0.2097 ml -1 and 11.17 sec. The corresponding pairs of ABP→E max and HR→E max step responses show that E max would decrease and increase, respectively, in response to step increases in ABP and HR. The average gain value of the ABP→E max step response and the average dominant time constant of the HR→E max step response are smaller than those of the CVP→E max step response. During the propranolol condition, the CVP→E max step response indicates that E max would not change in response to a step increase in CVP. The corresponding ABP→E max and HR→E max step responses similarly reveal blunted responses to steps increases in ABP and HR.
IV. DISCUSSION
In summary, we have investigated the cardiopulmonary baroreflex control of ventricular contractility in terms of E max in two conscious dogs. Our results suggest that, similar to the Bainbridge effect, the cardiopulmonary baroreflex responds to an increase (decrease) in CVP by increasing (decreasing) E max . This mechanism appears to be mediated by the β-sympathetic nervous system, as the E max response to a change in CVP was abolished following the administration of propranolol. These pilot results may be amongst, if not, the first to illustrate how the cardiopulmonary baroreflex controls ventricular contractility.
Further, our ancillary results here on the E max response to changes in ABP and HR are consistent with known physiology. In particular, we found that an ABP change produces an opposing change in E max , which is consistent with the negative feedback dynamics of the arterial baroreflex, while a HR change induces the same directional change in E max , which is congruent with the force-frequency relation. Moreover, the E max response to a HR change was markedly faster than to an ABP change. This result is in accord with the force-frequency relation being mediated by fast mechanical effects and the arterial baroreflex being governed by the sluggish sympathetic nervous system. Finally, as expected, the E max response to a change in ABP was eliminated after the administration of propranolol. (However, it is unclear why the E max response to a HR change was also blunted after the drug administration.) These physiologically consistent results add confidence to our new findings on the cardiopulmonary baroreflex control of ventricular contractility.
Our future efforts will focus on confirming the results reported herein in a larger number of animals. Ultimately, we believe that this line of research will translate to a significant advance in the understanding of baroregulatory physiology. 
